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Abstract: Repair of central nervous system (CNS) lesions is diffi- 
culted by the lack of ability of central axons to regrow, and the 
blocking by the brain astrocytes to axonal entry. We hypothesized 
that by using bridges made of porous biomaterial and permissive 
olfactory ensheathing glia (OEG), we could provide a scaffold to 
permit restoration of white matter tracts. We implanted porous 
polycaprolactone (PCL) bridges between the substantia nigra and 
the striatum in rats, both with and without OEG. We compared 
the number of tyrosine-hydroxylase positive (TH1) fibers cross- 
ing the striatal-graft interface, and the astrocytic and microglial 
reaction around the grafts, between animals grafted with and 
without OEG. Although TH1 fibers were found inside the grafts 
made of PCL alone, there was a greater fiber density inside the 
graft and at the striatal-graft interface when OEG was cografted. 
Also, there was less astrocytic and microglial reaction in those 
animals. These results show that these PCL grafts are able to 
promote axonal growth along the nigrostriatal pathway, and that 
cografting of OEG markedly enhances axonal entry inside the 
grafts, growth within them, and re-entry of axons into the CNS. 
These results may have implications in the treatment of diseases 
such as Parkinson’s and others associated with lesions of central 






Damage to the central nervous system (CNS), including stroke, 
trauma and neurodegenerative diseases, constitute the 
second cause of death and the first cause of disability 
worldwide. In order to treat these lesions, regenerative 
medicine has focused in trying to replace the lost neurons. 
However, the CNS is a very complex structure, where func- 
tion depends largely on maintaining long distance point to 
point connections between the different neuronal nuclei 
through axons contained in the white matter pathways. The 
CNS is very unpermissive for axonal regeneration. When a 
lesion occurs, the basal membrane is rapidly reconstituted 
and a glial scar is formed. Glial cells segregate inhibitory 
factors1 which impede axonal growth.2-5 This may be one of 
 
the causes of the lack of success of cell  therapy  to  treat  brain 
damage. For example, in Parkinson’s disease, where 
dopaminergic cells from the substantia nigra  projecting  their 
axons to the striatum are lost, clinical trials have tried  to 
replace the lost dopaminergic cells. Thus, new cells were 
placed at the striatum, in order to overcome the lack of 
spontaneous nigrostriatal pathway regeneration. However, 
the implanted cells were out of control causing the so-called 
dopaminergic storm, with involuntary movements and other 
unwanted side effects.6 
One of the possible solutions for this lack of ability of 
damaged axons to reestablish long distance connections is   to 
provide of a supporting guide for the axons toward the target 
structure.7-11 
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Contrary to what happens at the CNS, axons may grow after 
being severed within the peripheral nerves. Some approaches 
to overcome the above problem have used bridges made of 
peripheral nerve grafts into the CNS to enhance central axonal 
growth.12-16 However, issues of availability and histocompati- 
bility of peripheral nerve donors may favor the use of synthetic 
biomaterials.9,10 Among them, polycaprolactone (PCL) is an 
excellent candidate due to its integrative and biocompatibility 
characteristics.17,18 It can be used to produce macroporous 
scaffolds, permitting the outgrowth of axons as well as facilitat- 
ing the arrival of nutrients, and the disposal of metabolic 
waste.19-21 These structures have been used to repair other 
organs, such as the heart or the urinary bladder.22,23 
However, re-entry of axons into the CNS is blocked by the 
presence of astrocytes and the inhibitory factors referred 
above. The combined use of cells which have been shown to 
be permissive to this reentry, such as olfactory ensheathing 
glial (OEG) cells might overcome this problem.16,24-28 
It has been described that cells from the OEG may have a 
positive effect in degenerative lesions, promoting axonal 
growth and regeneration, and even remyelination and synap- 
tic reconnection of the damaged axon.29,30 This regenerative 
capacity may be due to the production of trophic factors, like 
SDF-1 of brain derived neurotrophic factor (BDNF).31 
In this experiment, we have implanted porous bridges 
made of PCL, with or without OEG cells embedded inside them, 
inside the brains of naive rats, between the substantia nigra 
compacta and the striatum, in order to test the ability  of these 
bridges to convey CNS axonal growth. 
 
MATERIAL AND METHODS 
All procedures were performed under the standard criteria 
for ethical management and care of the animals in accor- 
dance with the EC Council Directive of November 24, 1986, 
and approved by the local ethics  committee  of  the  Centro de 
Investigacion Principe Felipe de Valencia. 
 
OEG isolation and culture 
  
OEG cells were isolated from four adult homozygotic transgenic 
rats (Wistar-TgN[CAG-GFP]184 years) with constitutive expres- 
sion of enhanced green fluorescent protein (eGFP) (Rat 
Resource and Research Center, University of Missouri, accord- 
ing to the procedure described by Navarro et al.32 Briefly, rats 
were anesthetized with pentobarbital sodium (60 mg/kg, 
Sigma) and decapitated. The two outer layers of the olfactory 
bulb were dissected, minced, and then trypsinized with 0.25% 
trypsin and 0.03% collagen enzyme IV for 15 min at 378C. 
After two centrifugations (1000 rpm, 10 min), the pellet was 
sus- pended in Dulbecco’s Modified Eagle’s Medium 
(DMEM)/F12 (Gibco) with 10% fetal bovine serum (Gibco), 
1% glutamine (Hyclone), 2% penicillin–streptomycin 
(Hyclone), and 1% gen- tamicin (Hyclone) and seeded into a 
60-mm cell culture dish (Corning) with 5 3 106 cells and 
incubated for 24 h (378C and 5% CO2). Cells in passage 4 
were prepared to be implanted fol- lowing  the  method  
proposed  by  the  laboratory  of  Gómez- Pinedo et al.33 
Polymeric materials 
PCL (molecular weight (MW): 48,000, density 1.145 g/cm3; 
Polysciences) was employed to develop the porous materials. 
Poly(ethyl methacrylate) (PEMA) beads (Elvacite 2043; 
DuPont), having a size of around 200 1 25 mm, were used as 
the porogen material. Besides, ethanol (EtOH) (199.5%; 
Scharlau) and 1,4-dioxane (98% purity, Scharlab) were used 
in the scaffold fabrication procedure. Each of these materials 
was employed as received. 
 
Fabrication of scaffolds 
A solution of 10% (w/w) of PCL in 1,4-dioxane was mixed with 
an appropriate quantity of acrylic microspheres in a tef- lon 
mold and frozen using liquid nitrogen. The extraction of the 
frozen mold was carried out in cold ethanol at 2208C (eth- anol 
was changed three times over 3 days) and then porogen was 
leached using ethanol at 408C in a shaking bath. Ethanol was 
changed until no more porogen was detected in the wash- ing 
solution. Then samples were allowed to dry in air during 24 h 
and further dried in vacuum for 72 h. Samples were cut using 
a scalpel to dimensions 1 3 1 3 6 mm and sterilized using g-
ray irradiation at a standard dose of 15 kGy. 
 
Scanning electron microcopy observation 
For scaffold morphology characterization, samples were frac- 
tured in liquid nitrogen, mounted on copper stubs, and gold 
sputtered. The samples were observed with a JEOL JSM6300 




Porosity was calculated by gravimetric means. Samples were 
weighed dry, filled with ethanol under vacuum, and subse- 
quently weighed again. Porosity was calculated as the quo- 
tient of the volume of pores and the total apparent volume of 
the scaffold. The volume of pores was calculated as the ratio 
between the weighed mass of ethanol within the scaffold and 
ethanol density; the apparent volume occupied by the scaffold 
was taken as the sum of the pore volume and the polymer vol- 
ume, and the polymer volume was determined as the ratio of 
the weighed polymer mass and the density of PCL. Five inde- 
pendent measurements were performed. 
The PCL-grafts were stereotactically implanted using a 
procedure already described.34 Briefly, animals were anesthe- 
tized and placed in a stereotactic instrument permitting tra- 
jectories with different entry angles (Stellar, Stereotaxic 
Instrument 5100, Stoelting Co., IL). Coordinates were deter- 
mined for the insertion of a graft between the center of the 
striatum and substantia nigra pars compacta. The coordinates 
from bregma, according to the Paxinos and Watson34 atlas, 
were  21.5  mm  lateral  (X1),  25.6  mm  posterior  (Y1),  and 
28.4 mm below the dural surface (Z1) for the substantia nigra 
pars compacta, and 24.0 mm lateral (X2), 20.8 mm posterior 
(Y2), and 25.5. mm dorso-ventral (Z2) for the center of the 
striatum. The graft’s length (or distance between substantia 
nigra and striatum) measured 6 mm and the entry angles were 
alpha (cenital) 5 228.28 and beta (azimuthal) 5 27.58. A 






FIGURE 1. Scanning electron image of PCL shows a view of the inner 
porous  structure  of  the  scaffold.  It  presents  a  bimodal  pore size 
distribution, with large macropores around 250 lm interconnected and 
micropores with dimensions ranging from 30 to <5 lm. Porosity of the 
scaffold as measured by gravimetric means was  90.5 6 1.7%. 
Scale bar: 300 lm. 
 
 
PCL-grafts between the two targets without pushing or 
squeezing them, with a piston preventing the graft from slid- 
ing back. In the experimental group (n 5 8) we injected at the 
distal and proximal end of the PCL-grafts 2 mL of a suspension 
of OEG cells (5 3 104 cells), while in the control group (n 5 8) 
the PCL-grafts was implanted without further manipulation. 
Although the host animals had not been previously manipu- 
lated before the implant procedure, the insertion of the PCL- 
grafts could have produced a local mechanical lesion at the 
implant trajectory. 
Four weeks after grafting, animals were sacrificed through 
barbiturate overdose, perfused with 4% paraformaldehyde 
(PFA), removed brains postfixed in 4% PFA solution, and 
embedded  in  Tissue-Tek.  Transverse  sections  of  20  lm  were 
cut and mounted on slides. An anti-tyrosine hydroxylase (TH) 
monoclonal antibody (Millipore MAB318; 1:1000) was used to 
observe the substantia nigra, and the dopaminergic cells and 
fibers. An anti-glial fibrillary acidic protein (GFAP) polyclonal 
antibody (DakoCytomation Z0338; 1:300) was used to analyze 
the glial reaction, for microglial identification, a monoclonal 
anti-IBA-1 antiserum (Wako; 1:500) and an anti-green fluores- 
cent protein (GFP) polyclonal antibody (ABCAM AB13970; 
1:200), was used to label GFP cells, followed by Alexa second- 
ary antibody 488, 555 and 647 anti-mouse or anti-rabbit. 
Immunohistochemistry samples were observed in an 
optical microscope (Leica DM 6000B,  Leica  Microsystems) or 
a confocal microscope (Leica SP2, ABOS Leica Microsys- tems). 
To obtain confocal micrographs, each fluorochrome dye 
within the same field was scanned separately. 
Fluorescence images were quantified using the software 
included in the confocal microscope (Leica SP2, ABOS Leica 
Microsystems). To measure TH fibers, we applied a modification 
of the physical dissector method described by Reed, using the 
unbiased brick principle of the three-dimensional dissector.35,36 
In order to evaluate the microglial and glial reaction in  the 
area close to the striatal end of the graft (100 mm around), we 
used a modified version of Sholl rings.37 Briefly, the 
 
stereological graticule consists of concentric circles with 10 
lm  of distance  between each. The  cellular  somata with their 
visible branches were placed on the center of the graticule and 
the number of intersections (NoI) of radial glial cell-like 
processes projections within the graticule was counted. 
Quantitative results are expressed as mean 6 standard 
error of mean. Groups were tested for differences by per- 
forming t student test following a Mann Whitney test using 
Prism (GraphPad Software Inc., La Jolla, CA). Differences were 
considered statistically significant at a value p < 0.05. 
 
RESULT 
The biomaterial produced presented the structure of a scaf- 
fold with a high porosity. This can be shown in Figure 1, where 
pores of 300 um are shown beside 5 to 30 mm micropores 
contributing to connect between them, permit- ting the 
passing though of cells and fluids. 
All animals survived after the grafting procedure. There 
were no behavioral or neurologic deficits, and no seizures were 
observed. The brains showed no macroscopic signs of inflam- 
mation, infection or rejection of the biomaterial. Histological 
analysis with serial sections demonstrated that the graft was 
correctly placed between the two points chosen and integrated 
with the host brain. An astrocytic reaction was evident around 
the graft, without cavitations, edematous or necrotic areas, neu- 
trophil infiltrates or other histologic alterations suggesting 
rejection. This astroglial reaction was more evident in the grafts 
implanted without OEG cells, which were encapsulated by the 
scar and showed protoplasmatic astrocytes. When OEG had 
been cografted, only a mild astroglial reaction was observed, 
and the morphology of most of the astrocytes was similar to 
the intact areas of the brain located far from the implant: non- 
hypertrophic stellate astrocytes with fine filaments. The quanti- 
tative analysis of the astrocytic transformation in terms of 
number of GFAP marked cells per 500 mm2 reflects this differ- 
ence (Figure 2, p < 0.05). Figure 2 approximately here. 
Also, a discrete microglial reaction in the vicinity of the 
implanted biomaterial was observed. When OEG was cografted 
 
FIGURE 2. Mean density of GFAP marked cells around the implant in 
both groups. *p < 0.05. 
  
 
FIGURE 3. Quantification of the microglial transformation around the biomaterial, showing the expression of IBA-1 within concentric rings with 
10 lm of distance between each. Expression greater within the innermost rings indicates more ameboid shape, and expressio n within the outer 
most, a more branching shape. Microglial cells in resting state tend to be more branching. 
 
the morphology of microglia was similar to other normal brain 
areas (quiescent microglial cells), while grafts without OEG 
were surrounded by amoeboid rod-shaped microglial cells 
forming a small layer around the graft. (Figure 3, p < 0.05). 
TH1  fibers  were  seen  inside  the  grafts  (in  both cases) 
(Figures 4 and 5), although the fiber density was higher  when  
OEG  was  cografted  (Figures  5  and  6).  OEGs  were 
 
 
FIGURE 4. Confocal microscopic picture of the PCL only implant close to 
the substantia nigra pars compacta (SNpc), showing  a low density   of 
TH fibers within the biomaterial. BM, biomaterial; TH, tyrosine 
hydroxylase; DAPI, 40,6-diamidino-2-phenylindole. Scale bar: 200 lm. 
even seen migrating inside the grafts. Fiber count inside the 
graft showed a higher density at the substantia nigra end, and 
a progressive reduction of fiber density in the middle and in 
the striatal end of the graft (Table I, p < 0.05). 
 
DISCUSSION 
Results show that bridges made of PCL support the growth   of 
axons to connect two distant nuclei within the CNS. 
Up to now, the only way to produce this was inserting bio- 
logically derived materials, either endogenous or allogenic. 
Peripheral nerve grafts have been widely used due to their 
capacity to sustain axonal growth. Also, injection of biochemi- 
cals to inhibit astrocytic activity and create a local milieu per- 
missive to axonal growth. Collier and Springer37 were able, 
using peripheral nerve grafts with embryonic dopaminergic 
cells in hemiparkinsonian rats, to recover the neurotransmit- 
ter levels improving the motor activity of the damaged rats.38 
Wictorin et al. were able to show axons reaching the striatum 
through Schwann cell grafts in 6OHDA damaged rats, without 
an effect on motor behavior.39 The transplantation of fetal 
dopaminergic neuroblasts in damaged animals may generate a 
histological pattern resembling the nigrostriatal pathway 
suggesting a functional integration. 
However, up to now no one has demonstrated that the 
anatomical reconstruction is superior to simply grafting the stri- 
atum with dopaminergic neurons. One of the reasons for this may 
be the limited number of axons reaching their final target. The use 
of polymeric biomaterials oriented in longitudinal fas- cicles may 
be a means to obtain a richer axonal regrowth. 
The grafting procedure is original (previously reported in   
Gómez-Pinedo   et   al.)33   and   was   designed   to   implant 
peripheral nerve grafts. It was designed to overcome the 
difficulty of placing a flaccid material joining two desired 
nuclei within the CNS. It has been useful to implant bioma- 
terials with the consistency of PCL, the grafts being placed 
connecting the desired CNS nuclei. The procedure did not 
produce any observable side effects, in terms of general or 




FIGURE 5. Confocal microscopic picture of the PCL plus OEG implant, showing the OEG cells at the border of the biomaterial and a high er TH 
fiber density within the implant. TH fibers within the biomaterial. GFP, green fluorescent protein; BM, biomaterial; TH, tyro sin hydroxylase; DAPI, 
*. Scale bar: 75 lm 
 
Also, the PCL graft has shown to be biocompatible with the 
brain, integrating with the host tissue, not producing toxic side 
effects, as already described by other authors,19,21,22 thus able 
to provide a bridge between the two desired points within the 
brain, Cografting the OEG cells was associated with a better 
integration of PCL grafts with the host brain. PCL had already 
been shown to be permissive to neural growth. In vitro, neural 
cells grow over the surface of 2D films made of PCL and show 
a normal electrophysiologic activity.40,41 PCL has seldom been 
used in vivo in the CNS. Pérez-Garnés et al.42 showed that PCL 
can safely be implanted over the meninges, without an 
inflammatory response. Other biomaterials have been used 
more frequently in central neural implants, such as hyaluronic 
acid, chitosan, or carbon nanotubes.9-11 However, 
 
FIGURE 6. Detail of the interior of the PCL plus OEG implant, where 
PCL is easily produced, is biocompatible, modulates the 
microglial and astrocytic response and is permissive for the 
growth of neurites, although its production is expensive and 
needs more safety studies in humans. PCL also showed to be 
compatible to OEG cografting. The use of OEG and other cells 
which enhance axonal growth associated to biomaterials has 
already been tested43,44 and could be a proper strategy to 
adapt the artificial grafts to the repair of brain injuries. 
Although there was an astrocytic reaction around the 
graft, trying to encapsulate the graft, it was mild enough to 
permit the entry of axons. Also, there was a microglial reac- 
tion, indicating a local brain reaction to a foreign body, not 
important enough to shown signs of graft rejection. Astro- 
cytic and microglial reaction was lower when OEG was cog- 
rafted, indicating that OEG promotes a microenvironment 
with less inflammation, which could constitute the mecha- 
nism of its enhancing effect on axonal regeneration. 
Axons positive to TH1 (i.e., axons from dopaminergic cells) 
were seen inside the grafts both when PCL was implanted 
alone and when OEG was cografted. As TH1 fibers have been 
seen crossing the graft interface at both ends of the grafts, and 
 





Number of TH1 Fibers  
Zone PCL PCL-OECs 
SN interface-graft 106 6 8.2 133 6 11.1 
MW 57 6 4.8 72 6 9.9 
ST interface–graft 39 6 4.1 62 6 3.4 
TH positive axons are seen within the biomaterial, as well a high den-    
sity of cells colonizing the implant. a Volume analyzed (0.077 mm3). 
 
dopaminergic fibers grow only from the SN part of it, it is possi- 
ble to conclude that the fibers enter the graft at the nigral end, 
and also that they exit the graft at the striatal end. 
This is supported by the fact that fiber density is highest at 
the nigral end and progressively lower along the direction 
toward the striatal end. Cografting of cells permissive to  fiber 
reentry into the CNS, such as OEG, markedly increases this 
effect, being even more marked at the striatal end, that  is, it 
enhances axonal entry inside the graft, growth within the graft 
and specially reentry of axons back into the CNS. OEGs were 
seen migrating inside the grafts. The fact  that OEG cells have 
been found along the graft  and not only at  the extremes, were 
they were injected, may  support  the  idea that these cells 
migrate inside the  graft  and  enhance the axonal growth along 
the graft. They also greatly enhance the reentry of axons inside 
the brain. 
OEGs permit the entry of axons from the olfactory nerves 
into the olfactory bulb24-26,45 and have been extensively used a 
permissive cells for axonal reentry in spinal cord and spinal 
root repair.27,33 In our study, OEGs have favored the entry of 
dopaminergic axons into the graft and they have also permitted 
the reentry of axons back into the brain. 
We chose implanting our grafts close to the substantia 
nigra pars compacta due to the specific ability of dopami- 
nergic fibers to regrow.16,46 
This study is limited because we have not shown rein- 
nervation of the tissues from axons coming from the graft. 
Also, it has to be followed by studies showing  histological and 
functional reinnervation in animal models of axonal injury or 
neurodegeneration, such as models of parkinson- ism, in order 
to demonstrate the potentially clinical useful- ness of this 
strategy. 
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